Literature DB >> 28414609

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

Glenn J Bubley1, Steven P Balk1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28414609     DOI： 10.1200/JCO.2017.72.8808

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Targeting the androgen receptor and overcoming resistance in prostate cancer.

Authors:  David J Einstein; Seiji Arai; Steven P Balk
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

2.  Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

Authors:  Marco A De Velasco; Yurie Kura; Kazuko Sakai; Yuji Hatanaka; Barry R Davies; Hayley Campbell; Stephanie Klein; Youngsoo Kim; A Robert MacLeod; Koichi Sugimoto; Kazuhiro Yoshikawa; Kazuto Nishio; Hirotsugu Uemura
Journal:  JCI Insight       Date:  2019-09-05

3.  GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis.

Authors:  Ricardo A Cordova; Jagannath Misra; Parth H Amin; Anglea J Klunk; Nur P Damayanti; Kenneth R Carlson; Andrew J Elmendorf; Hyeong-Geug Kim; Emily T Mirek; Bennet D Elzey; Marcus J Miller; X Charlie Dong; Liang Cheng; Tracy G Anthony; Robero Pili; Ronald C Wek; Kirk A Staschke
Journal:  Elife       Date:  2022-09-15       Impact factor: 8.713

4.  CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Authors:  Xi Chen; Yechen Wu; Xinan Wang; Chengdang Xu; Licheng Wang; Jingang Jian; Denglong Wu; Gang Wu
Journal:  Eur J Med Res       Date:  2022-07-02       Impact factor: 4.981

Review 5.  A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Ramona F Curpan; Yousef M Hawsawi; Ping Fan; V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2017-11-21       Impact factor: 5.678

6.  CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.

Authors:  Justin H Hwang; Rand Arafeh; Ji-Heui Seo; Sylvan C Baca; Megan Ludwig; Taylor E Arnoff; Lydia Sawyer; Camden Richter; Sydney Tape; Hannah E Bergom; Sean McSweeney; Jonathan P Rennhack; Sarah A Klingenberg; Alexander T M Cheung; Jason Kwon; Jonathan So; Steven Kregel; Eliezer M Van Allen; Justin M Drake; Matthew L Freedman; William C Hahn
Journal:  Elife       Date:  2022-05-12       Impact factor: 8.713
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.